Investment
Features
FeesSafety
Academy
More
Pluang+

Compare L3Harris Technologies Inc (LHX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

L3Harris Technologies IncTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

L3Harris Technologies Inc vs Recursion Pharmaceuticals Inc — how do they compare? L3Harris Technologies Inc trades at $290.9 (market cap $53.26B), while Recursion Pharmaceuticals Inc trades at $3.28 (market cap $1.81B). The key difference: L3Harris Technologies Inc is far larger — about 29.4× Recursion Pharmaceuticals Inc's market cap, and L3Harris Technologies Inc pays a 1.75% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

LHXRXRX
Market Cap
$53.26B$1.81B
Sector
IndustrialsHealth
52-Week High
$378.48$6.79
52-Week Low
$270.21$2.84
Enterprise Value
$63.71B$1.33B
Dividend Yield
1.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

L3Harris Technologies Inc

LHX trades at $290.66, up 0.32% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with revenue up 8% and a record $42 billion backlog. Recent news highlights contract wins, including a U.S. Space Force satellite deal and PAC-3 production expansion, supporting growth prospects. Fundamentals show steady revenue growth to $21.87 billion in 2025 and improving net margins, though valuation ratios like P/E of 28.89 are elevated relative to historical averages.

Outlook is positive with analyst consensus favoring buys (73%) and a $319.33 price target implying ~10% upside. Risks include execution on large contracts, debt levels, and geopolitical dependencies. The stock offers a dividend yield near 1.7%, with cash flow strength supporting shareholder returns amid defense sector tailwinds.

Recursion Pharmaceuticals Inc

RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.

The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About L3Harris Technologies Inc

L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.

Read more on LHX

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX